Nomura keeps JPY 3,800.00 target for Daiichi Sankyo stock

Published on 10/17/2026 at 21:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due October 30, 2026. Daiichi Sankyo stock costs JPY 2,740.50 on October 16, 2026, up 3.38 percent versus Tokyo's October 15 close.

Target and reporting date

Nomura maintained a JPY 3,800.00 target on October 13, 2026.
Daiichi Sankyo is scheduled to report results on October 30, 2026.
Daiichi Sankyo stock stood at JPY 2,740.50 on October 16, 2026, up 3.38 percent versus the Tokyo close of October 15, 2026.
Market capitalization was JPY 4.99 trillion and the P/E ratio was 20.76.

Daiichi Sankyo, JP3475350009, Illustration mit AI erstellt.

Nomura maintained a Buy rating and a JPY 3,800.00 price target for Daiichi Sankyo on October 13, 2026, according to Markets Insider. The target stood 38.66 percent above the last Tokyo quote of JPY 2,740.50. Daiichi Sankyo stock was up 3.38 percent on October 16, 2026, versus the Tokyo Stock Exchange prior close of October 15, 2026.

Results date sets the next marker

Daiichi Sankyo has scheduled its fiscal second-quarter financial results briefing for October 30, 2026. The investor calendar lists the session for 5:30 p.m. to 7:30 p.m. Japan time, giving the market a defined date for the next company update, according to Daiichi Sankyo.

Stock sits above its yearly low

The October 16 Tokyo quote was JPY 2,740.50, with the session ending at 3:30 p.m. JST. The price stood 14.66 percent above the 52-week low of JPY 2,390.00 and 34.28 percent below the 52-week high of JPY 4,170.00. The move was measured against a prior close of JPY 2,651.00, while the quote's reported average volume was 6,452,127 shares.

Valuation before the October date

Daiichi Sankyo had a market capitalization of JPY 4.99 trillion and a P/E ratio of 20.76 on October 16, 2026. The scheduled October 30 results date is therefore the next concrete calendar marker for the valuation. The company operates in pharmaceuticals, with oncology products and antibody-drug conjugates among its major business areas.

Comparison with peers

Daiichi Sankyo (Tokyo Stock Exchange, JPY): plus 3.38 percent, P/E 20.76, market capitalization JPY 4.99 trillion
Takeda Pharmaceutical (Tokyo Stock Exchange, JPY): plus 0.65 percent, P/E 55.47, market capitalization JPY 9.90 trillion
Astellas Pharma (Tokyo Stock Exchange, JPY): plus 2.63 percent, P/E 11.91, market capitalization JPY 4.34 trillion

Trading view for investors

The Tokyo quote placed Daiichi Sankyo above its yearly low but well below its yearly high on October 16, 2026. Nomura's JPY 3,800.00 target and the October 30 reporting date provide two separate markers for how the market may assess the next company update.